Cargando…
Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis
Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. Treatment modalities are currently limited to surgical resection, chemotherapy and radiotherapy. Increases in survival rate over the previous decades are negligible, further pinpoint...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871709/ https://www.ncbi.nlm.nih.gov/pubmed/33681797 http://dx.doi.org/10.1136/bmjno-2020-000069 |
_version_ | 1783649062797443072 |
---|---|
author | Kan, Liyen Katrina Drummond, Kate Hunn, Martin Williams, David O'Brien, Terence J Monif, Mastura |
author_facet | Kan, Liyen Katrina Drummond, Kate Hunn, Martin Williams, David O'Brien, Terence J Monif, Mastura |
author_sort | Kan, Liyen Katrina |
collection | PubMed |
description | Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. Treatment modalities are currently limited to surgical resection, chemotherapy and radiotherapy. Increases in survival rate over the previous decades are negligible, further pinpointing an unmet clinical need in this field. There is a continual struggle with the development of effective glioma diagnostics and therapeutics, largely due to a multitude of factors, including the presence of the blood–brain barrier and significant intertumoural and intratumoural heterogeneity. Importantly, there is a lack of reliable biomarkers for glioma, particularly in aiding tumour subtyping and measuring response to therapy. There is a need for biomarkers that would both overcome the complexity of the disease and allow for a minimally invasive means of detection and analysis. This is a comprehensive review evaluating the potential of current cellular, proteomic and molecular biomarker candidates for glioma. Significant hurdles faced in glioma diagnostics and therapy are also discussed here. |
format | Online Article Text |
id | pubmed-7871709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-78717092021-03-04 Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis Kan, Liyen Katrina Drummond, Kate Hunn, Martin Williams, David O'Brien, Terence J Monif, Mastura BMJ Neurol Open Review Gliomas are the most common central nervous system malignancies and present with significant morbidity and mortality. Treatment modalities are currently limited to surgical resection, chemotherapy and radiotherapy. Increases in survival rate over the previous decades are negligible, further pinpointing an unmet clinical need in this field. There is a continual struggle with the development of effective glioma diagnostics and therapeutics, largely due to a multitude of factors, including the presence of the blood–brain barrier and significant intertumoural and intratumoural heterogeneity. Importantly, there is a lack of reliable biomarkers for glioma, particularly in aiding tumour subtyping and measuring response to therapy. There is a need for biomarkers that would both overcome the complexity of the disease and allow for a minimally invasive means of detection and analysis. This is a comprehensive review evaluating the potential of current cellular, proteomic and molecular biomarker candidates for glioma. Significant hurdles faced in glioma diagnostics and therapy are also discussed here. BMJ Publishing Group 2020-08-24 /pmc/articles/PMC7871709/ /pubmed/33681797 http://dx.doi.org/10.1136/bmjno-2020-000069 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Review Kan, Liyen Katrina Drummond, Kate Hunn, Martin Williams, David O'Brien, Terence J Monif, Mastura Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis |
title | Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis |
title_full | Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis |
title_fullStr | Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis |
title_full_unstemmed | Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis |
title_short | Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis |
title_sort | potential biomarkers and challenges in glioma diagnosis, therapy and prognosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871709/ https://www.ncbi.nlm.nih.gov/pubmed/33681797 http://dx.doi.org/10.1136/bmjno-2020-000069 |
work_keys_str_mv | AT kanliyenkatrina potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis AT drummondkate potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis AT hunnmartin potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis AT williamsdavid potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis AT obrienterencej potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis AT monifmastura potentialbiomarkersandchallengesingliomadiagnosistherapyandprognosis |